The Magazine for Sleep Professionals
Saturday, September 19, 2026
Nox Health announced that it has closed the acquisition of Somryst, the first and only FDA-approved prescription digital therapeutic that delivers effective, first-line treatment for adults with chronic insomnia. The addition of Somryst expands Nox Health’s comprehensive suite of tools and programs that address a critical and growing demand for sleep […]
Pear Therapeutics, Inc., announced the availability of Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia. Somryst addresses the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), an evidence-based approach […]
